: ,
The FDA approved once-daily oral semaglutide (Wegovy) at 25 mg on 22 December 2025, making it the first oral GLP-1 approved specifically for chronic weight management in the US
(6) Mason C, Xiao L, Duggan C, Imayama I, Foster-Schubert KE, Kong A, Campbell KL, Wang CY, Alfano CM, Blackburn GL, Pollack M, McTiernan A
Lipo-C may support fat metabolism in the liver and help the body process fat more effectively, potentially contributing to stubborn-fat reduction over time when combined with caloric restriction and movement
By the end of treatment, gastrointestinal symptoms had improved by approximately 80 percent and core autism symptoms had improved by approximately 24 percent on professional evaluation [14]
In short, while theres still so much that needs sorting out, weve got a breakthrough family of drugs that are already exceeding lofty expectations